5-aminolaevulinic acid cystectomy cystoscopy hexylaminolaevulinate narrow-band imaging photodynamic diagnosis commercial or financial relationships that could be construed as a potential conflict of interest.

Carcinoma Transitional Cell/*diagnostic imaging/*pathology Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Staging/methods Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/*pathology

Data Systems Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Invasiveness Predictive Value of Tests Reproducibility of Results Urinary Bladder Neoplasms/*diagnostic imaging/pathology Bladder cancer Magnetic resonance imaging Meta-analysis Muscle invasive Systematic review Vesical Imaging Reporting and Data System

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.

*Carcinoma Transitional Cell Evidence-Based Medicine Humans *Radiology Societies Medical United States *Urinary Bladder Neoplasms/diagnostic imaging Auc Appropriate Use Criteria Appropriateness Criteria Bladder cancer Muscle invasive bladder cancer Nonmuscle invasive bladder cancer Surveillance Transitional cell carcinoma Urothelial cancer

Vi-rads bladder cancer bladder cancer staging inter-reader agreement multiparametric magnetic resonance imaging muscle-invasive bladder cancer

5-ala 5-aminolaevulinic acid Hal Pdd accuracy meta-analysis bladder cancer blue light cystoscopy cystoscopy hexaminolevulinate narrow band imaging photodynamic diagnosis fluorescence consultant for Janssen Ferring Photocure Taris Spectrum Pacific Edge QED Abbvie Johnson & Johnson Seattle Genetics Nucleix Aduro and BMS. Ashish Kamat is is a consultant for Photocure. Mihir Desai is a consultant for Procept Biorobotics and Auris Surgical. Yair Lotan is a consultant for Photocure. Angela Smith is an investigator for Urogen and a consultant for FerGene Urogen and Merck.

Humans Muscle Skeletal/*pathology Neoplasm Invasiveness ROC Curve Radiography/*methods Research Design Urinary Bladder Neoplasms/*diagnosis Bladder cancer Diagnostic imaging Magnetic resonance imaging

Coloring Agents Humans Indocyanine Green Lymph Node Excision *Lymphatic Metastasis/diagnostic imaging *Lymphography Male Pelvis *Prostatic Neoplasms/diagnostic imaging/pathology Sentinel Lymph Node Biopsy *Urinary Bladder Neoplasms/diagnostic imaging/pathology Cáncer de Próstata Ganglio centinela Linfadenectomía Lymph node dissection Prostate cáncer Sentinel lymph node Verde de Indocianina

Carcinoma Transitional Cell/*diagnostic imaging/pathology/surgery Cystectomy Humans Lymph Nodes/*diagnostic imaging/pathology Lymphatic Metastasis/diagnostic imaging Magnetic Resonance Imaging Neoplasm Staging Positron Emission Tomography Computed Tomography Sensitivity and Specificity Tomography X-Ray Computed Urinary Bladder Neoplasms/*diagnostic imaging/pathology/surgery Bladder cancer Computed tomography Positron emission tomography Transitional cell carcinoma

Aminolevulinic Acid/*chemistry Cystoscopy/methods Humans Image Interpretation Computer-Assisted/*methods Narrow Band Imaging/methods Photosensitizing Agents/*chemistry Urinary Bladder Neoplasms/metabolism/pathology/*surgery Narrow band imaging bladder cancer diagnostic performance photodynamic diagnosis white light-guided cystoscopy

Contrast Media Diagnosis Differential Female Humans Lymphatic Metastasis/*diagnostic imaging/pathology Magnetic Resonance Imaging/*methods Male Prostatic Neoplasms/*pathology Sensitivity and Specificity Urinary Bladder Neoplasms/*pathology Mri bladder cancer lymph node metastasis meta-analysis prostate cancer

Adult Aged Aged 80 and over Female Humans *Magnetic Resonance Imaging Male Middle Aged *Neoplasm Staging/methods/standards Urinary Bladder Neoplasms/*diagnostic imaging bladder cancer diagnostic accuracy magnetic resonance imaging staging systematic review

Chemoradiotherapy/*methods Combined Modality Therapy Cystectomy/*adverse effects/methods Disease-Free Survival Female Humans Male Middle Aged Neoplasm Metastasis Robotic Surgical Procedures/*adverse effects/methods Treatment Outcome Urinary Bladder Neoplasms/diagnostic imaging/*therapy Bladder cancer Cystectomy Multi-modality treatment Port-site metastasis Rare complications

*Acetates *Carbon Carbon Radioisotopes Carcinoma Transitional Cell/*diagnostic imaging/pathology *Choline Humans Likelihood Functions Lymph Nodes/*diagnostic imaging/pathology Lymphatic Metastasis Neoplasm Staging Odds Ratio Positron Emission Tomography Computed Tomography ROC Curve Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/pathology Bladder cancer C-11 acetate C-11 choline Lymph node Pet/ct Staging

Adult Aged Aged 80 and over Humans Magnetic Resonance Imaging/standards Middle Aged Muscle Neoplasms/*diagnosis Neoplasm Invasiveness Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis Bladder cancer Local staging Magnetic resonance imaging Meta-analysis Muscle-invasive bladder cancer Systematic review

Fluorodeoxyglucose F18 Humans Lymph Nodes/*diagnostic imaging/pathology Lymphatic Metastasis/diagnosis/*diagnostic imaging/pathology Neoplasm Staging/methods Positron Emission Tomography Computed Tomography/*methods ROC Curve Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/pathology/surgery Bladder cancer F-18 fluorodeoxyglucose Lymph node Positron emission tomography/computed tomography Staging

*Aminolevulinic Acid Cystectomy/methods Disease-Free Survival Humans Neoplasm Recurrence Local *Photosensitizing Agents Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnostic imaging/*surgery 5-aminolevulinic acid non-muscle invasive bladder cancer photodynamic diagnosis recurrence-free survival transurethral resection